The aim of the present study was to evaluate the effect of the e13a2 and e14a2 BCR::ABL1 transcripts on DMR and TFR in a large series of CP-CML patients treated with IM and 2G-TKI. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.